^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | ipatasertib (RG7440) (PI3K inhibitor, AKT inhibitor) + A-1331852 (Bcl-xL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins
Published date:
07/10/2021
Excerpt:
In addition, we identified the AKT inhibitor ipatasertib and two BH3 mimetics targeting these anti-apoptotic proteins, S63845 and A-1331852, as new potential therapies for this type of cancer. Therefore, we postulate the sequential inhibition of both proteins using BH3 mimetics as a new treatment option for refractory and relapsed ER+ breast cancer tumors.
DOI:
10.3390/cells10071659
